Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity

@article{Vejpongsa2014Topoisomerase2A,
  title={Topoisomerase 2$\beta$: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity},
  author={Pimprapa Vejpongsa and Eth Yeh},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2014},
  volume={95}
}
Anthracyclines are powerful chemotherapy agents that are still widely used today. However, their clinical use is limited by the development of dose‐dependent cardiotoxicity. Recently, we showed that topoisomerase 2β (Top2β) is required for anthracycline to induce DNA double‐strand breaks and changes in the transcriptome, leading to mitochondrial dysfunction and generation of reactive oxygen species. Furthermore, deleting Top2β from cardiomyocytes prevented the development of anthracycline… Expand
View on Wiley
ncbi.nlm.nih.gov
139 Citations
Highly Influential Citations
5
Background Citations
34
Methods Citations
2
Results Citations
3

139 Citations

Citation Type

Citation Type

Review Statins in Anthracycline-induced Cardiotoxicity: Rac and Rho, and the Heartbreakers Official Journal of the Cell Death Differentiation Association
  • 2017
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
TLDR
Off-label use of statins or novel Rac1 inhibitors might represent a promising pharmacological approach to gain control over chronic cardiotoxicity by interfering with key mechanisms of anthracycline-induced cardiomyocyte cell death. Expand
Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature.
TLDR
Data from the literature have indicated that PI3Kγ and Rac1 are potential targets with therapeutic advantages in cancer therapy; molecules that target these proteins can simultaneously attenuate Dox-induced cardiotoxicity and enhance its anticancer activity. Expand
Cardiotoxicity of anthracycline therapy: current perspectives
TLDR
According to previous clinical trials, the major high-risk factors for anthracycline-induced cardiotoxicity are age, body weight, female gender, radiotherapy, and other diseases such as Down syndrome, familial dilated cardiomyopathy, diabetes and hypertension. Expand
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
  • R. Damiani, D. Moura, +4 authors J. Saffi
  • Chemistry, Medicine
  • Toxicology in vitro : an international journal published in association with BIBRA
  • 2018
TLDR
It is demonstrated that as well as increasing DNA damage and inducing apoptotic cell death, DPQ enhances DOX- and MTX-mediated cytotoxicity in H9c2. Expand
Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation.
TLDR
The present review aimed to discuss ANTs-induced cardiac injury from different points of view, updating and focusing on oxidative stress and inflammation, since these pathways are not exclusive or independent from each other but they together importantly contribute to the complexity of AN Ts-induced multifactorial cardiotoxicity. Expand
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
TLDR
Current strategies for primary and secondary prevention of anthracycline-induced cardiotoxicity resulting from newly recognized molecular mechanisms are outlined and knowledge gaps requiring further investigation are identified. Expand
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
TLDR
Prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops and strategies for protecting the myocardium from anthracycline are reviewed. Expand
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets
TLDR
Therapeutic strategies relieving oxidative stress and inflammation hold promise to prevent heart failure development or at least to mitigate cardiac damage, although further evidence is needed on their efficacy. Expand
Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.
TLDR
Though a panel of natural products and herb extracts demonstrate protective effects on DOX-induced cardiotoxicity in cells and animal models, their therapeutic potentials for clinical needs further investigation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
TLDR
It is shown that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes, and this results suggest that dex Razoxane antagonizesDoxorubsicin-induced DNA damage through its interference with Top2beta, which could implicate Top2 beta indoxorUBicin cardiotoxicity. Expand
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
TLDR
It is shown here that VP-16-induced carcinogenesis involves mainly the β rather than the α isozyme of Top2, suggesting the importance of developing Top2α-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies. Expand
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
TLDR
The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised. Expand
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*
TLDR
It is shown that NK314, a novel synthetic benzo[c]phenanthridine alkaloid, targets Top2α and not Top2β in vivo, and that a series of human knock-out cell lines are useful in assessing DNA damage and repair induced by potential topoisomerase-targeting agents. Expand
New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.
TLDR
A survey of DXR-induced defects in different steps of cardiac energy metabolism, including reduction of oxidative capacity of mitochondria, changes in the profile of energy substrate utilization, disturbance of energy transfer between sites of energy production and consumption, as well as defects in energy signaling are presented. Expand
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
TLDR
Cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Expand
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
TLDR
It is suggested that doxorubicin treatment induces acute cardiac dysfunction and reduces cardiac mass via p53-dependent inhibition of mTOR signaling and that loss of myocardial mass, and not cardiomyocyte apoptosis, is the major contributor to acute doxorbicin cardiotoxicity. Expand
Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells
TLDR
The expression level of topo II beta is intra- and inter-individually variable, and may in part determine the apoptotic response to doxorubicin and other anthracyclines. Expand
Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
TLDR
Monitoring IRP activities in H9c2 rat embryo cardiomyocytes exposed to DOX or to analogues revealed that IRP-2 was inactivated only by ROS, serving guidelines for designing anthracyclines that spare iron homeostasis and induce less severe cardiotoxicity. Expand
Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines.
TLDR
DEX appears to be a promising drug in the treatment of AML and warrants further clinical study involving novel drug combinations, and the effects of DEX in combination with any of the anthracyclines were schedule dependent. Expand
...
1
2
3
4
5
...